- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07698535
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Droga: Docetaxel
- Procedimiento: Tomografía computarizada
- Procedimiento: Colección de muestras biológicas
- Procedimiento: Escaneo PET PSMA
- Droga: Lutecio Lu 177 Vipivotida Tetraxetan
- Procedimiento: Tomografía de fotón único y tomografía computarizada
- Procedimiento: Cell-free Circulating Tumor DNA Assay
Descripción detallada
OUTLINE:
CYCLES 1 AND 2: Patients receive 177Lu-PSMA-617 intravenously (IV) over 20-30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection with ctDNA TF testing at baseline and C2D1. Patients with undetectable ctDNA TF (< 3%) on C2D1 continue to receive 177Lu-PSMA-617 as above in the absence of disease progression or unacceptable toxicity. Patients with detectable ctDNA TF (≥ 3%) on C2D1 are randomized to 1 of 2 arms.
CYCLE 3+ ARM I: Starting with cycle 3, patients receive 177Lu-PSMA-617 IV over 20-30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
CYCLE 3+ ARM II: Starting with cycle 3, patients receive docetaxel IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Additionally, all patients undergo PSMA positron emission tomography (PET) during screening, single photon emission computed tomography (SPECT)/computed tomography (CT) on study, and additional blood sample collection as well as CT throughout the study.
After completion of study treatment, patients are followed up every 12 weeks for up to 1 year.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Michael Schweizer, MD
- Número de teléfono: 206-606-6252
- Correo electrónico: schweize@uw.edu
Ubicaciones de estudio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutch/University of Washington Cancer Consortium
-
Investigador principal:
- Michael Schweizer, MD
-
Contacto:
- Michael Schweizer, MD
- Número de teléfono: 206-606-6252
- Correo electrónico: schweize@uw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Willing and able to provide informed consent
- Adult males ≥ 18 years age
- History of histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine or small cell differentiation. If histology is not available, patients must have metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes)
- Evidence of metastatic disease on bone scan or CT scan
Patient must have evidence of castration- resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e., ≤ 50 mg/dL)
- Serum/plasma PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Prior treatment and progression on at least one androgen receptor pathway inhibitor (ARPI), in either castration-sensitive or castration-resistant setting
- Eligible for treatment with either 177Lu-PSMA-617 or docetaxel as per their respective Food and Drug Administration (FDA) labels
- Absolute neutrophil count ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Hemoglobin ≥ 9 g/dL
- Creatinine clearance ≥ 50 ml/min (calculated by Cockcroft-Gault formula)
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome (direct bilirubin ≤ 1.5 x ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN. For patients with known Gilbert's Syndrome they must be ≤ 3 x ULN
- Able to comply with study requirements including provision of peripheral blood samples at specified time points for correlative studies
Exclusion Criteria:
- Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition that could interfere with patient safety or provision of informed consent to participate in this study
- Evidence of metastatic neuroendocrine/small cell prostate cancer (NEPC). Note: baseline biopsy is not required
- Patients receiving any systemic therapy (aside from a luteinizing hormone-releasing hormone [LHRH] analogue) or radiotherapy within 2 weeks prior to study treatment
- Persistent toxicities (CTCAE grade > 2) from prior cancer therapy, excluding alopecia and stable neuropathy
- Patients considered a poor medical risk due to a serious, uncontrolled medical disorder or active, uncontrolled infection. Examples include, but are not limited to uncontrolled seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
- Patients who are known to be serologically positive for human immunodeficiency virus (HIV) and a CD4 count < 200
- Patients with known active hepatitis (i.e. hepatitis B or C). Prior hepatitis C infection is allowed as long as polymerase chain reaction (PCR) is negative
- Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
- Serious cardiac disorder, including but not limited to uncontrolled ventricular arrhythmia, recent (within 12 months) myocardial infarction, resting electrocardiogram (ECG) indicating Fridericia's corrected QT interval prolongation > 500ms, or congenital long QT syndrome
- Prior systemic chemotherapy with taxane chemotherapy, including in hormone sensitive setting (e.g. docetaxel or cabazitaxel)
Brain metastases or active epidural disease (treated epidural disease is permitted)
- Note: baseline brain imaging is not required
- Contraindication to prednisone therapy including poorly controlled diabetes mellitus
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)
Patients receive 177Lu-PSMA-617 IV over 20-30 minutes on day 1 of each cycle.
Cycles repeat every 6 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo blood sample collection with ctDNA TF testing at baseline and C2D1.
Patients with undetectable ctDNA TF (< 3%) on C2D1 continue to receive 177Lu-PSMA-617 as above in the absence of disease progression or unacceptable toxicity.
Patients with detectable ctDNA TF (≥ 3%) on C2D1 are randomized to 1 of 2 arms.
Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.
|
Someterse a una tomografía computarizada
Otros nombres:
Someterse a la recolección de muestras de sangre
Otros nombres:
Someterse a PSMA PET
Otros nombres:
Dado IV
Otros nombres:
Someterse a SPECT/CT
Otros nombres:
Undergo ctDNA TF testing
Otros nombres:
|
|
Comparador activo: Cycle 3+ Arm I (177Lu-PSMA-617)
Starting with cycle 3, patients receive 177Lu-PSMA-617 IV over 20-30 minutes on day 1 of each cycle.
Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.
|
Someterse a una tomografía computarizada
Otros nombres:
Someterse a la recolección de muestras de sangre
Otros nombres:
Someterse a PSMA PET
Otros nombres:
Dado IV
Otros nombres:
Someterse a SPECT/CT
Otros nombres:
|
|
Comparador activo: Cycle 3+ Arm II (docetaxel)
Starting with cycle 3, patients receive docetaxel IV on day 1 of each cycle.
Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.
|
Dado IV
Otros nombres:
Someterse a una tomografía computarizada
Otros nombres:
Someterse a la recolección de muestras de sangre
Otros nombres:
Someterse a PSMA PET
Otros nombres:
Someterse a SPECT/CT
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomization
Periodo de tiempo: Up to 2 cycles (Cycle length = 6 weeks)
|
Will be analyzed descriptively.
Among patients who initiate lutetium Lu 177 vipivotide tetraxetan and undergo cycle (C) 2 day (D) 1 ctDNA tumor fraction assessment, the number (and proportion among those recruited) with detectable ctDNA tumor fraction who undergo randomization will be reported with a two-sided 95% Wilson confidence interval.
|
Up to 2 cycles (Cycle length = 6 weeks)
|
|
Number of patients screened, enrolled, evaluable for C2D1 ctDNA tumor fraction and for who cycle 3 is administered
Periodo de tiempo: Up to cycle 3 administration (Cycle length = 6 weeks)
|
Will report the number of patients screened, enrolled, evaluable for C2D1 (week 13) ctDNA tumor fraction, classified as having detectable versus undetectable ctDNA tumor fraction, and for who cycle 3 is administered.
Reasons for failure to undergo C1D28 ctDNA assessment or randomization will be tabulated.
|
Up to cycle 3 administration (Cycle length = 6 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Radiographic progression free survival (PFS)
Periodo de tiempo: From randomization to disease progression, clinical progression, or death, whichever occurs first, assessed up to 1 year
|
Will be estimated in the subset of patients who undergo randomization.
Disease progression assessed per modified Response Evaluation Criteria in Solid Tumors criteria or the Prostate Cancer Working Group 3 criteria for bone lesions.
Clinical progression as determined by the treating physician.
Will be estimated using the Kaplan-Meier method.
Differences between groups will be evaluated using the log-rank test and the hazard ratio from a Cox regression model with treatment group as the predictor variable following assessment of proportional hazards.
Will also visualize PFS point estimates and 95% confidence interval (CI) bands over time and report median and 95% CIs of PFS for each group.
|
From randomization to disease progression, clinical progression, or death, whichever occurs first, assessed up to 1 year
|
|
Overall survival
Periodo de tiempo: From the start of treatment until death from any cause, assessed up to 1 year
|
Will be estimated in the subset of patients who undergo randomization.
Will be estimated using the Kaplan-Meier method.
Differences between groups will be evaluated using the log-rank test and the hazard ratio from a Cox regression model with treatment group as the predictor variable following assessment of proportional hazards.
|
From the start of treatment until death from any cause, assessed up to 1 year
|
|
Prostate-specific antigen (PSA) PFS
Periodo de tiempo: From the start of treatment until PSA progression, assessed up to 1 year
|
Will be estimated in the subset of patients who undergo randomization.
Will be estimated using the Kaplan-Meier method.
Differences between groups will be evaluated using the log-rank test and the hazard ratio from a Cox regression model with treatment group as the predictor variable following assessment of proportional hazards.
|
From the start of treatment until PSA progression, assessed up to 1 year
|
|
Proportion of patients with a ≥ 50% decline in PSA from baseline (PSA50) response rate
Periodo de tiempo: Up to 1 year
|
Will be estimated in the subset of patients who undergo randomization.
Will be reported as a percentage with 95% CI calculated using Wilson's method.
Changes in PSA from baseline, with patients achieving PSA50, may be visualized using waterfall plots.
|
Up to 1 year
|
|
Duration of response
Periodo de tiempo: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 1 year
|
Will be estimated in the subset of patients who undergo randomization.
|
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Michael Schweizer, MD, Fred Hutch/University of Washington Cancer Consortium
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Químicos orgánicos
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Taxaides
- Ciclodecanos
- Diterpenos
- Hidrolasas peptídicas
- Metaloproteasas
- Carboxipeptidasas
- Exopeptidasas
- Metaloexopeptidasas
- Docetaxel
- Pluvicto
- Manejo de muestras
- Glutamato carboxipeptidasa II
Otros números de identificación del estudio
- RG1126448
- NCI-2026-03971 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- FHIRB0021269 (Otro identificador: Fred Hutch/University of Washington Cancer Consortium)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .